Clinical analysis of EGFR‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group

BACKGROUND: In the LUX‐Lung 3 and LUX‐Lung 6 trials, afatinib improved overall survival in previously untreated patients with EGFR 19del mutated non‐small cell lung cancer (NSCLC) compared to chemotherapy. The appropriate management of adverse events and dose reduction of afatinib are important for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonehara, Kei, Kobayashi, Takashi, Tateishi, Kazunari, Morozumi, Nobutoshi, Yoshiike, Fumiaki, Hachiya, Tsutomu, Ono, Yasushi, Takasuna, Keiichirou, Agatsuma, Toshihiko, Masubuchi, Takeshi, Matsuo, Akemi, Tanaka, Hozumi, Morikawa, Akio, Hanaoka, Masayuki, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501023/
https://www.ncbi.nlm.nih.gov/pubmed/31006178
http://dx.doi.org/10.1111/1759-7714.13047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501023/
https://www.ncbi.nlm.nih.gov/pubmed/31006178
http://dx.doi.org/10.1111/1759-7714.13047

Ejemplares similares